UNODC compiles data on thriving drug markets, noting a 30% rise in use over the last decade yet remaining mostly silent on human rights impact of drug control.
ECOWAS acknowledges the importance of ensuring access to harm reduction services by removing socio-structural barriers, including through decriminalisation.
OPIS argues evidence for the therapeutic potential of psilocybin in addressing this debilitating condition warrants immediate reform to allow for legal access and further research.
Santini et al. discuss how adequate and flexible funding is required to respond to the harms and barriers in accessing services experienced by sex workers..
The INCB's annual report reflects both progress and shortcomings in the Board's approach to drug control, further integrating human rights considerations whilst showing a degree of inflexibility in relation to national criminal justice reforms.
The DLA outlines initiatives to protect the health and safety of people in custodial settings in the context of the pandemic situation, as well as their limitations.
This short document serves as a practical guide for civil society on possible ways to use the Model Drug Law in advancing drug policy reform in West Africa and beyond.
IDPC, TB/HIV Care and ARASA demonstrate how drug policy reform is a sustainable development issue that African countries need to urgently address to achieve the SDGs.
The Global Commission on Drug Policy urges global leaders to review the international drug control conventions in order to build a serious, modern and responsible drug control framework based on science and evidence and centred on human rights.
IDPC and APCOF summarise discussions from a multi-stakeholder meeting addressing the links between criminalisation and human rights violations, regional policy developments and avenues for future reform.
Collaborating under the Support. Don't Punish campaign, IDPC & ARASA provide an overview of the key questions that drug decriminalisation advocates should consider to demand reform.
